This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saussele S, Lauseker M, Müller MC, Gratwohl A, Beelen D, Bunjes DW et al2567 Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: update on the survival outcome following allogeneic HSCT after imatinib failure; results of the German CML Study IV. 56th ASH Annual Meeting and Exposition; 6–9 December 2014; San Francisco, CA, USA.
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
Barrett AJ, Ito S . The role of stem cell transplantation for chronic myelogenous leukaemia in the 21st century. Blood 2015; 125: 3230–3235.
Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421–1423.
Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905–912.
Gratwohl A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749–756.
Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukaemia in the imatinib era. Clin Lymphoma Myeloma 2009; 9 (Suppl 3): S261–S265.
Jabbour E, Cortes J, Santos FPS, Jones D, O’Brien S, Rondon G et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011; 117: 3641–3647.
Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49: 1146–1154.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872–874.
Weiden PL, Flournoy N, Thomas ED . Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukaemia. Blood 2008; 112: 3500–3507.
Egan DN, Beppu L, Radich JP . Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. Biol Blood Marrow Transplant 2015; 21: 184–189.
Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ . A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91: 663–666.
Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukaemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083–4090.
Acknowledgements
We would like to thank colleagues at the Australasian Bone Marrow Transplant Recipient Registry and at the following hospitals for responding to the data spreadsheet questionnaire: The Alfred, Auckland City Hospital, Christchurch Hospital, Royal Adelaide Hospital, Royal Brisbane and Women’s Hospital, The Royal Melbourne Hospital, Royal Prince Alfred Hospital, Royal Perth Hospital, St Vincent’s Hospital Sydney, Wellington Hospital and Westmead Hospital. We thank Jane Apperley (London) and Timothy Hughes (Australia) for helpful suggestions and critical reading of an earlier draft of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kruger, P., Cooney, J., Nivison-Smith, I. et al. All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand. Bone Marrow Transplant 51, 1400–1403 (2016). https://doi.org/10.1038/bmt.2016.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.143